Kubota Naoto, Terauchi Yasuo, Kubota Tetsuya, Kumagai Hiroki, Itoh Shinsuke, Satoh Hidemi, Yano Wataru, Ogata Hitomi, Tokuyama Kumpei, Takamoto Iseki, Mineyama Tomoka, Ishikawa Michiro, Moroi Masao, Sugi Kaoru, Yamauchi Toshimasa, Ueki Kohjiro, Tobe Kazuyuki, Noda Tetsuo, Nagai Ryozo, Kadowaki Takashi
Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655.
J Biol Chem. 2006 Mar 31;281(13):8748-55. doi: 10.1074/jbc.M505649200. Epub 2006 Jan 23.
Thiazolidinediones have been shown to up-regulate adiponectin expression in white adipose tissue and plasma adiponectin levels, and these up-regulations have been proposed to be a major mechanism of the thiazolidinedione-induced amelioration of insulin resistance linked to obesity. To test this hypothesis, we generated adiponectin knock-out (adipo-/-) ob/ob mice with a C57B/6 background. After 14 days of 10 mg/kg pioglitazone, the insulin resistance and diabetes of ob/ob mice were significantly improved in association with significant up-regulation of serum adiponectin levels. Amelioration of insulin resistance in ob/ob mice was attributed to decreased glucose production and increased AMP-activated protein kinase in the liver but not to increased glucose uptake in skeletal muscle. In contrast, insulin resistance and diabetes were not improved in adipo-/-ob/ob mice. After 14 days of 30 mg/kg pioglitazone, insulin resistance and diabetes of ob/ob mice were again significantly ameliorated, which was attributed not only to decreased glucose production in the liver but also to increased glucose uptake in skeletal muscle. Interestingly, adipo-/-ob/ob mice also displayed significant amelioration of insulin resistance and diabetes, which was attributed to increased glucose uptake in skeletal muscle but not to decreased glucose production in the liver. The serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo-/-ob/ob mice were unchanged after 10 mg/kg pioglitazone but were significantly reduced to a similar degree after 30 mg/kg pioglitazone. Moreover, the expressions of TNFalpha and resistin in adipose tissues of ob/ob and adipo-/-ob/ob mice were unchanged after 10 mg/kg pioglitazone but were decreased after 30 mg/kg pioglitazone. Thus, pioglitazone-induced amelioration of insulin resistance and diabetes may occur adiponectin dependently in the liver and adiponectin independently in skeletal muscle.
噻唑烷二酮类药物已被证明可上调白色脂肪组织中脂联素的表达及血浆脂联素水平,并且这些上调作用被认为是噻唑烷二酮类药物改善与肥胖相关的胰岛素抵抗的主要机制。为验证这一假说,我们培育了具有C57B/6背景的脂联素基因敲除(adipo-/-)ob/ob小鼠。给予10mg/kg吡格列酮14天后,ob/ob小鼠的胰岛素抵抗和糖尿病症状显著改善,同时血清脂联素水平显著上调。ob/ob小鼠胰岛素抵抗的改善归因于肝脏中葡萄糖生成减少以及AMP激活的蛋白激酶增加,而非骨骼肌中葡萄糖摄取增加。相比之下,adipo-/-ob/ob小鼠的胰岛素抵抗和糖尿病症状未得到改善。给予30mg/kg吡格列酮14天后,ob/ob小鼠的胰岛素抵抗和糖尿病症状再次显著改善,这不仅归因于肝脏中葡萄糖生成减少,还归因于骨骼肌中葡萄糖摄取增加。有趣的是,adipo-/-ob/ob小鼠的胰岛素抵抗和糖尿病症状也显著改善,这归因于骨骼肌中葡萄糖摄取增加,而非肝脏中葡萄糖生成减少。给予10mg/kg吡格列酮后,ob/ob和adipo-/-ob/ob小鼠的血清游离脂肪酸和甘油三酯水平以及脂肪细胞大小未发生变化,但给予30mg/kg吡格列酮后均显著降低至相似程度。此外,给予10mg/kg吡格列酮后,ob/ob和adipo-/-ob/ob小鼠脂肪组织中TNFα和抵抗素的表达未发生变化,但给予30mg/kg吡格列酮后均降低。因此,吡格列酮诱导的胰岛素抵抗和糖尿病改善可能在肝脏中依赖脂联素发生,而在骨骼肌中独立于脂联素发生。